These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9055134)

  • 21. Factors influencing the prediction of steady state concentrations of digoxin.
    Nakamura T; Kakumoto M; Yamashita K; Takara K; Tanigawara Y; Sakaeda T; Okumura K
    Biol Pharm Bull; 2001 Apr; 24(4):403-8. PubMed ID: 11305603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics of digoxin in pediatric patients.
    Martín-Suárez A; Falcao AC; Outeda M; Hernández FJ; González MC; Quero M; Arranz I; Lanao JM
    Ther Drug Monit; 2002 Dec; 24(6):742-5. PubMed ID: 12451291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of troglitazone on steady-state pharmacokinetics of digoxin.
    Loi CM; Knowlton PW; Stern R; Randinitis EJ; Vassos AB; Koup JR; Sedman AJ
    J Clin Pharmacol; 1998 Feb; 38(2):178-83. PubMed ID: 9549650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women.
    Roman D; Bramson C; Ouellet D; Randinitis E; Gardner M
    J Clin Pharmacol; 2005 Dec; 45(12):1407-12. PubMed ID: 16291716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic interaction of sparfloxacin and digoxin.
    Johnson RD; Dorr MB; Hunt TL; Conway S; Talbot GH
    Clin Ther; 1999 Feb; 21(2):368-79. PubMed ID: 10211539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The serum digoxin concentration: ten questions to ask.
    Cauffield JS; Gums JG; Grauer K
    Am Fam Physician; 1997 Aug; 56(2):495-503, 509-10. PubMed ID: 9262530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin.
    Toothaker RD; Corey AE; Valentine SN; Agnew JR; Parekh N; Moehrke W; Thompson GA; Powell JH
    J Clin Pharmacol; 2005 Jul; 45(7):773-80. PubMed ID: 15951467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
    Zhou H; Horowitz A; Ledford PC; Hubert M; Appel-Dingemanse S; Osborne S; McLeod JF
    J Clin Pharmacol; 2001 Oct; 41(10):1131-9. PubMed ID: 11583482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum).
    Johne A; Brockmöller J; Bauer S; Maurer A; Langheinrich M; Roots I
    Clin Pharmacol Ther; 1999 Oct; 66(4):338-45. PubMed ID: 10546917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of digoxin in Korean patients.
    Nagaraja NV; Park YJ; Jeon S; Sands CD; Derendorf H
    Int J Clin Pharmacol Ther; 2000 Jun; 38(6):291-7. PubMed ID: 10890577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetic investigation for optimization of amiodarone therapy in Japanese patients.
    Araki R; Yukawa E; Nakashima MN; Fukuchi H; Sasaki H; Yano K; Nakashima M
    Ther Drug Monit; 2011 Dec; 33(6):750-6. PubMed ID: 22105593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of digoxin in Thai pediatric patients.
    Preechagoon Y; Somsaard P; Petcharattana S
    J Med Assoc Thai; 2009 Oct; 92(10):1324-35. PubMed ID: 19845241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive performance of serum digoxin concentration in patients with congestive heart failure by a hyperbolic model based on creatinine clearance.
    Konishi H; Shimizu S; Chiba M; Minouchi T; Koida M; Yamaji A
    J Clin Pharm Ther; 2002 Aug; 27(4):257-65. PubMed ID: 12174027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An assessment of population-based and Bayesian methods to individualize digoxin doses shortly after the start of therapy for atrial fibrillation.
    Chrystyn H; Dean S
    J Clin Pharm Ther; 1991 Jun; 16(3):177-85. PubMed ID: 1869597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive performance of four pharmacokinetic methods for calculating digoxin dosage.
    el-Sayed YM
    J Clin Pharm Ther; 1995 Oct; 20(5):297-304. PubMed ID: 8576297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations.
    Bauer LA; Horn JR; Pettit H
    Ther Drug Monit; 1996 Feb; 18(1):46-52. PubMed ID: 8848820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of oral cibenzoline on steady-state digoxin concentrations in healthy volunteers.
    Khoo KC; Givens SV; Parsonnet M; Massarella JW
    J Clin Pharmacol; 1988 Jan; 28(1):29-35. PubMed ID: 3350991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis.
    Fukuchi H; Nakashima M; Araki R; Komiya N; Hayano M; Yano K; Sasaki H; Yukawa E
    J Clin Pharm Ther; 2009 Jun; 34(3):329-36. PubMed ID: 19646079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetic analysis of digoxin in Chinese neonates and infants.
    Gong Y; Chen Y; Li Q; Li Z
    J Pharmacol Sci; 2014; 125(2):142-9. PubMed ID: 24837877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis.
    Suematsu F; Yukawa E; Yukawa M; Minemoto M; Ohdo S; Higuchi S; Goto Y
    Biopharm Drug Dispos; 2002 Jul; 23(5):173-81. PubMed ID: 12116048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.